Research pass: medium Supplement · Capsule SKIP-FOR-NOW MEDIUM
DHEA (Dehydroepiandrosterone)
Extended Research
◈
Extended Research
◈
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Our verdict SKIP-FOR-NOW MEDIUM
At 20yo Dylan's endogenous DHEA-S is at lifetime peak (~age 20-25); exogenous supplementation is hormonally redundant and can perturb HPG axis with no upside. Would reconsider only if bloodwork (~June 2026) shows unexpectedly low DHEA-S — extremely unlikely at this age.
Research pass: medium
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype) | SKIP | endogenous DHEA-S at peak; no demonstrated benefit in healthy young men; risks (HPG modulation, E2 elevation, acne) without offsetting upside. Brain effects (NMDA/GABA neurosteroid modulation) are vastly better captured by targeted nootropics. |
30-50, executive maintenance | OPTIONAL-ADD | if DHEA-S documented low (<200 µg/dL men). Otherwise skip — decline at 30-50 is real but mild. |
50+, mild cognitive decline | STRONG-CANDIDATE | if DHEA-S below age-adjusted reference range. Safest cleanest deficiency-replacement use case. 25-50mg/day with quarterly bloodwork. |
Anxiety-prone | M | — pro-arousal NMDA modulation can worsen anxiety in some; not first-line. |
High athletic load, tested status | WADA-BANNED | in and out of competition. Disqualifying for any sanctioned athlete. (Dylan is untested → not disqualifying for him, just irrelevant.) |
Sleep-disordered | A | — pro-arousal neurosteroid effects can worsen sleep. |
Recovery-focused (post-injury, post-illness) | P | adjunct in older adults with post-illness HPA dysregulation; not relevant young. |
Strength/anabolic-focused | W | signal. The "DHEA as anabolic" framing of the early 2000s did not hold up — net androgen yield from 50mg is small and aromatization eats half of it. Real anabolics dominate. |
- Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)SKIP
endogenous DHEA-S at peak; no demonstrated benefit in healthy young men; risks (HPG modulation, E2 elevation, acne) without offsetting upside. Brain effects (NMDA/GABA neurosteroid modulation) are vastly better captured by targeted nootropics.
- 30-50, executive maintenanceOPTIONAL-ADD
if DHEA-S documented low (<200 µg/dL men). Otherwise skip — decline at 30-50 is real but mild.
- 50+, mild cognitive declineSTRONG-CANDIDATE
if DHEA-S below age-adjusted reference range. Safest cleanest deficiency-replacement use case. 25-50mg/day with quarterly bloodwork.
- Anxiety-proneM
— pro-arousal NMDA modulation can worsen anxiety in some; not first-line.
- High athletic load, tested statusWADA-BANNED
in and out of competition. Disqualifying for any sanctioned athlete. (Dylan is untested → not disqualifying for him, just irrelevant.)
- Sleep-disorderedA
— pro-arousal neurosteroid effects can worsen sleep.
- Recovery-focused (post-injury, post-illness)P
adjunct in older adults with post-illness HPA dysregulation; not relevant young.
- Strength/anabolic-focusedW
signal. The "DHEA as anabolic" framing of the early 2000s did not hold up — net androgen yield from 50mg is small and aromatization eats half of it. Real anabolics dominate.
▸ Subjective experience (deep)
At 20-25mg in a young man with normal levels: usually subtle to nothing. Some users report mild libido bump, slightly more acne/oily skin, and occasionally mild irritability or emotional reactivity (pro-androgenic). At 50-100mg: more reliable androgenic effects (acne, hair shedding in predisposed) and more aromatization (mild estrogenic side effects — water retention, occasionally nipple sensitivity). Onset is gradual (days to weeks); no acute "felt" dose. Discontinuation is uneventful but transient HPG suppression has been documented — endogenous testosterone may dip mildly for a few weeks.
▸ Tolerance + cycling deep dive
- Tolerance buildup: minimal — DHEA doesn't downregulate its own receptors meaningfully, but the HPG axis adapts (exogenous → less endogenous).
- Recommended cycle: when used in older adults, often continuous; younger users sometimes cycle 8 weeks on / 4 off to allow HPG recovery.
- Reset protocol: discontinuation alone — endogenous DHEA-S returns within weeks; HPG axis typically recovers within 4-8 weeks.
▸ Stacking deep dive
Synergistic with
- None relevant for Dylan's age. In the older-deficient context, DHEA is sometimes paired with pregnenolone, low-dose testosterone, or vitamin D — but those are post-50 protocols.
Avoid stacking with
- [enclomiphene] — both modulate the HPG axis from different angles; combining without bloodwork-driven rationale risks E2 elevation (DHEA → aromatization) layered onto enclomiphene's SERM-driven endogenous T rise. Coordinate, don't combine blind.
- [testosterone-enanthate] — exogenous testosterone already saturates androgen receptors and shuts down endogenous production; DHEA on top adds estrogenic load via aromatization with no androgenic benefit. Counterproductive on TRT.
- Aromatase-driving stacks (high-dose zinc deficiency states, high body fat) — amplify E2 conversion.
Neutral / safe co-administration
- Most of V4 stack (omega-3, magnesium, citicoline, NAC, etc.) — no meaningful interactions.
▸ Drug interactions deep dive
- CYP3A4 substrate — modest. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice in large quantities) can elevate DHEA exposure.
- Aromatase inhibitors (anastrozole, letrozole) — block DHEA → E2 conversion, shifting balance toward androgens. Not a pairing for a 20yo without specific indication.
- SSRIs / mood medications — case reports of mania induction in bipolar-spectrum users.
- Insulin sensitivity — DHEA modestly improves insulin sensitivity in older adults; minor relevance.
▸ Pharmacogenomics
- CYP3A4 / CYP3A5 polymorphisms affect DHEA metabolism modestly.
- CYP19A1 (aromatase) variants — high-activity aromatase variants will push more DHEA → E2, shifting the risk profile estrogenic.
- AR CAG repeat length — shorter repeats = more sensitive androgen receptors = more pronounced androgenic side effects per unit substrate.
- 23andMe will surface some of these (June 2026 results) — but for a 20yo, the question is moot regardless.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| OTC | iHerb / Amazon (Doctor's Best, Life Extension, NOW Foods) | $8-15 / 90-180 caps | high | 25mg and 50mg tabs widely available US |
| OTC (micronized) | Pure Encapsulations, Designs for Health | $20-35 / 60 caps | high | Better absorption claim |
| Rx (EU / banned regions) | Pharmacy Rx as "prasterone" | varies | high | Not relevant for US user |
Not relevant for Dylan's protocol — listed for completeness.
▸ Biomarkers to track (deep)
Not applicable — not on protocol. If hypothetically considered:
- Baseline (before starting): DHEA-S, total testosterone, free testosterone, estradiol (sensitive assay), SHBG, LH, FSH, lipids, fasting insulin
- During use: Same panel at 8-12 weeks
- Post-cycle (if cycled): Same panel 4-6 weeks after cessation to confirm HPG recovery
▸ Controversies / open debates Live debate
- "Anti-aging" framing. The 1990s-2000s "DHEA = fountain of youth" hype far outran the evidence. Real-world effect in older deficient adults is modest (well-being, body comp, libido); replacement is reasonable in deficiency, but it's not a longevity drug.
- Cognition signal. Mechanistically plausible (NMDA/GABA neurosteroid), clinically thin. Cochrane-level reviews are unimpressed.
- Cancer risk debate unresolved. No RCT has been long enough or large enough to settle. Mechanistic concern is real; clinical signal is absent. Most endocrinologists treat it as a "avoid in personal/family history" caution.
- Women vs men response asymmetry. DHEA replacement is more clearly beneficial in women (especially postmenopausal and adrenal-insufficient women) than in men, where exogenous testosterone is usually the cleaner intervention if T-deficiency is the issue.
- WADA status. Banned despite being endogenous — because exogenous administration measurably alters T/E ratio and DHEA-S/cortisol ratios. A perpetual headache for tested athletes.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-FOR-NOW (MEDIUM confidence). 20yo, endogenous DHEA-S almost certainly at peak; no evidence for benefit in healthy young men; modest HPG/E2 risk for zero gain. Reconsider only if June 2026 bloodwork (or any future panel) shows unexpectedly low DHEA-S — vanishingly unlikely at this age but the only path to changing the verdict.
▸ Open questions / gaps Open
- Dylan's actual DHEA-S level. ~June 2026 bloodwork will settle this. If it's in the upper-normal-young-adult range (expected: 400-600 µg/dL), DHEA stays SKIP indefinitely. If unexpectedly low (<200), revisit.
- Family history of hormone-sensitive cancers — not yet captured in profile (flagged as TBD). Relevant if DHEA ever became a candidate.
- 23andMe CYP19A1 / AR CAG data — would refine the side-effect risk profile if DHEA were ever considered, but doesn't change the core "endogenous peak, no upside" calculus.
- Crossover with stress/HPA-axis state. DHEA-S/cortisol ratio is a proposed (but not validated) HPA-allostatic-load marker; some interest in DHEA as cortisol-buffer in chronic stress. No actionable signal yet.
▸ Sources (full, with our context)
- Arlt W et al. "Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency." NEJM 1999;341(14):1013-1020. PMID: 10502590 — Cleanest deficiency-replacement RCT; n=24 women with adrenal insufficiency, 50 mg/day DHEA × 4 months crossover; restored DHEA-S, modest mood + sexual function improvement.
- Villareal DT, Holloszy JO. "Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and Men: A Randomized Controlled Trial." JAMA 2004;292(18):2243-2248. PMID: 15536111 — n=56 (28M / 28F, age 65-78), 50 mg/day × 6 months; visceral fat −13 cm² vs +3 cm² (p=0.001), subcutaneous fat −13 cm² vs +2 cm² (p=0.003), insulin sensitivity improved. Body composition signal in older adults.
- Nair KS et al. "DHEA in Elderly Women and DHEA or Testosterone in Elderly Men." NEJM 2006;355(16):1647-1659. PMID: 17050889 — Mayo Clinic 2-year RCT, n=87 men + 57 women age 60+; 75 mg/day men, 50 mg/day women. Negative trial: no improvement in body composition, physical performance, insulin sensitivity, or quality of life. The largest, longest, and methodologically cleanest healthy-elderly DHEA trial — and it failed. Critical counterweight to Villareal 2004's positive signal.
- Orentreich N, Brind JL, Rizer RL, Vogelman JH. "Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations Throughout Adulthood in Men." J Clin Endocrinol Metab 1984;59(3):551-555. PMID: 6235241 — Foundational lifecourse data establishing the ~2%/year decline pattern; the most-cited DHEA-S age-trajectory paper.
- Villareal DT, Holloszy JO. "DHEA Enhances Effects of Weight Training on Muscle Mass and Strength in Elderly Women and Men." Am J Physiol Endocrinol Metab 2006;291(5):E1003-E1008. PMID: 16787962 — Follow-up to JAMA 2004; n=56, 50 mg/day + weight training × 6 months. Augmented muscle mass + strength gains over training alone in older adults. The strongest age-related-decline replacement signal layered on top of resistance training.
- Jankowski CM et al. "Effects of Dehydroepiandrosterone Replacement Therapy on Bone Mineral Density in Older Adults: A Randomized, Controlled Trial." J Clin Endocrinol Metab 2006;91(8):2986-2993. PMID: 16735495 — n=140 (70 men + 70 women), 50 mg/day × 12 months; modest hip + spine BMD increase in older women with low baseline DHEA-S; signal weaker in men. Bone-density evidence base for DHEA replacement.
- Grimley Evans J et al. "Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people." Cochrane Database 2006 (and subsequent updates). — Cognition: insufficient evidence.
- WADA Prohibited List 2026 — DHEA listed under S1.1b (anabolic androgenic steroids, endogenous).